Abstract
The blood-brain barrier (BBB) not only impedes the influx of intravascular substances from blood to brain, but also promotes transport of substances from blood to brain or from brain to blood through several transport systems such as carrier-mediated transport, active efflux transport, and receptor-mediated transport systems. The multidrug resistance transporter P-glycoprotein (P-gp) is an ATP-dependent efflux pump and contributes to efflux of undesirable substances such as amyloid-β (Aβ) proteins from the brain into the blood as well as many drugs such as anti-cancer drugs. The inhibition of P-gp has favorable and unfavorable effects on living bodies. P-gp deficiency at the BBB induces the increase of Aβ deposition in the brain of an Alzheimer disease mouse model. It is also known that the Aβ deposition is inversely correlated with P-gp expression in the brains of elderly non-demented humans. However, the transient inhibition of P-gp by antidepressants enables medicines such as anti-cancer drugs to enter the brain. Concerning Aβ clearance in the brain, the low-density lipoprotein receptor-related protein 1 (LRP1) is a major efflux transporter for Aβ, while the receptor for advanced glycation end products (RAGE) is a major influx transporter for Aβ across the BBB. Dysfunction of the BBB with efflux and influx transporters may contribute to the pathogenesis of some degenerative neuronal disorders. This review will focus on several transporters and discuss how medicines pass the BBB to reach the brain parenchyma.
Current Medicinal Chemistry
Title: Transporters in the Brain Endothelial Barrier
Volume: 17 Issue: 12
Author(s): M. Ueno, T. Nakagawa, B. Wu, M. Onodera, C.-l. Huang, T. Kusaka, N. Araki and H. Sakamoto
Affiliation:
Keywords: Aβ, BBB, LRP1, P-gp, RAGE
Abstract: The blood-brain barrier (BBB) not only impedes the influx of intravascular substances from blood to brain, but also promotes transport of substances from blood to brain or from brain to blood through several transport systems such as carrier-mediated transport, active efflux transport, and receptor-mediated transport systems. The multidrug resistance transporter P-glycoprotein (P-gp) is an ATP-dependent efflux pump and contributes to efflux of undesirable substances such as amyloid-β (Aβ) proteins from the brain into the blood as well as many drugs such as anti-cancer drugs. The inhibition of P-gp has favorable and unfavorable effects on living bodies. P-gp deficiency at the BBB induces the increase of Aβ deposition in the brain of an Alzheimer disease mouse model. It is also known that the Aβ deposition is inversely correlated with P-gp expression in the brains of elderly non-demented humans. However, the transient inhibition of P-gp by antidepressants enables medicines such as anti-cancer drugs to enter the brain. Concerning Aβ clearance in the brain, the low-density lipoprotein receptor-related protein 1 (LRP1) is a major efflux transporter for Aβ, while the receptor for advanced glycation end products (RAGE) is a major influx transporter for Aβ across the BBB. Dysfunction of the BBB with efflux and influx transporters may contribute to the pathogenesis of some degenerative neuronal disorders. This review will focus on several transporters and discuss how medicines pass the BBB to reach the brain parenchyma.
Export Options
About this article
Cite this article as:
Ueno M., Nakagawa T., Wu B., Onodera M., Huang C.-l., Kusaka T., Araki N. and Sakamoto H., Transporters in the Brain Endothelial Barrier, Current Medicinal Chemistry 2010; 17 (12) . https://dx.doi.org/10.2174/092986710790827816
DOI https://dx.doi.org/10.2174/092986710790827816 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Food Addiction in Clinical Research
Current Pharmaceutical Design Prenatal Pregabalin Exposure Alters Postnatal Pain Sensitivity and Some Behavioral Responses in Adult Offspring Rats
Current Drug Safety Age-related Changes in Pharmacodynamics: Focus on Drugs Acting on Central Nervous and Cardiovascular Systems
Current Drug Metabolism Comparison of Glucocorticoid Receptor- and Epigenetically Regulated Genes in Proliferating Versus Growth-Arrested Neuro-2a Cells
CNS & Neurological Disorders - Drug Targets The Neurovascular Protection Afforded by Delayed Local Hypothermia after Transient Middle Cerebral Artery Occlusion
Current Neurovascular Research Using Microgravity for Defining Novel Anti-Atherosclerotic Therapy
Current Genomics Magnetic Resonance Imaging of Iron in Parkinsons Disease
Current Medical Imaging Cytotoxic and Radio-sensitizing Effects of Polyphenolic Acetates in a Human Glioma Cell Line (BMG-1)
Current Pharmaceutical Design From the Editors Perspective:New Directions and New Sources for Stem Cells [Hot Topic: Stem Cells (Guest Editor: Feng C. Zhou)]
Current Neurovascular Research Transitional Polytherapy: Tricks of the Trade for Monotherapy to Monotherapy AED Conversions
Current Neuropharmacology Biochemical and Therapeutic Effects of Antioxidants in the Treatment of Alzheimers Disease, Parkinsons Disease, and Amyotrophic Lateral Sclerosis
Current Drug Targets - CNS & Neurological Disorders Treponema, Iron and Neurodegeneration
Current Alzheimer Research Advances in Chagas Disease Chemotherapy
Anti-Infective Agents in Medicinal Chemistry The Dual Transporter Inhibitor Duloxetine: A Review of its Preclinical Pharmacology, Pharmacokinetic Profile, and Clinical Results in Depression
Current Pharmaceutical Design Circulating Biomarkers of Collagen Metabolism and Prognosis of Heart Failure with Reduced or Mid-Range Ejection Fraction
Current Pharmaceutical Design A Glance Over the Cannabinoid Machinery to Design New Anti- Angiogenic Compounds
Mini-Reviews in Medicinal Chemistry Zebrafish as a Model Organism to Study Melatonin Mechanisms and Treatments
Current Psychopharmacology Platelet Glycoprotein IIb / IIIa Inhibition and its Clinical Use
Current Medicinal Chemistry - Cardiovascular & Hematological Agents From Multiple PAR1 Receptor/Protein Interactions to their Multiple Therapeutic Implications
Current Topics in Medicinal Chemistry DeepSSPred: A Deep Learning Based Sulfenylation Site Predictor Via a Novel nSegmented Optimize Federated Feature Encoder
Protein & Peptide Letters